Skip to content
DataLookout
Menu

vGRID SBRTNCT05727787

vGRID SBRT: A Phase I Clinical Trial in Unresectable or Metastatic HCC

StatusRecruiting
PhaseNot applicable
Primary completion (estimated)

At risk: Primary completion moved 2 years later.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 6 versions: 6 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Primary completion pushed from Aug 31, 2026 to Aug 31, 2028
    • Eligibility criteria expanded, about 18 words
  2. Notable Primary completion date: May 28, 2025 to Aug 31, 2026
    • Study completion date: Dec 28, 2025 to Aug 31, 2028
    v5
  3. Minor Primary completion date: Feb 28, 2025 to May 28, 2025
    • Study completion date: Feb 28, 2025 to Dec 28, 2025
    v4
  4. Notable Eligibility criteria shortened, about 173 wordsv3
  5. Notable Trial status: Not Yet Recruiting to Recruitingv2 Show 4 more changesShow less
    • Eligibility criteria expanded, about 246 words
    • Start date changed from estimate of Feb 20, 2023 to Feb 23, 2023
    • Site details revised
    • Study title expanded, about 2 words
  6. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Maximum tolerated dose (MTD) of Single Fraction GRID SBRT
Timeframe: First day of post-GRID SBRT through 3 month post-radiation

Secondary (5)

Local control utilizing RECIST v1.1 for HCC.
Regional failure utilizing RECIST v1.1 for HCC.
Progression free survival (PFS)
Time to Progression (TTP)
Molecular correlatives: TCR repertoire analysis.

Arms and interventions

Single fraction SBRT 27 GyExperimental

vGRID SBRT 3+3 dose escalation, single fraction, one day cycle length

Radiation: Stereotactic Body Radiation Treatment

Sites

1 site in 1 country

  • University of Kansas Medical CenterKansas City, Kansas, United States